Evaluation of the Safety and Potential Therapeutic Effects of Cordstem-ST in Patients With Cerebral Infarction
NCT ID: NCT02378974
Last Updated: 2024-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
18 participants
INTERVENTIONAL
2015-02-28
2017-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
NCT03378414
Phase-dependent Evaluation of Motor Cortex Excitability With TMS in Stroke
NCT04968743
Motor Performance in Chronic Stroke Patients
NCT00110175
Improving Motor Learning in Stroke Patients
NCT00067197
Clinical Trial on the Safety and Efficacy of Optimized Transcranial Direct Current Stimulation for the Swallowing Function in Patients With Post-Stroke Dysphagia
NCT06305949
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Cordstem-ST cells or Placebo on day 0
Cordstem-ST
Placebo
Cohort 2
Cordstem-ST cells or Placebo on day 0 and day 7
Cordstem-ST
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cordstem-ST
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects who are able to receive intravenous Cordstem-ST Transplantation within 7 days (168 hours) of stroke onset
3. Subjects with diagnosis of Cerebral Infarction confirmed by the following criteria assessed at the screening visit
* NIHSS score between 5 and 20 (inclusive)
* Acute ischemic lesion involving anterior circulation territory identified in the diffusion weighted MRI
4. Signed informed consent
Exclusion Criteria
2. Subjects who are suspected to undergo endarterectomy during the study period. Subjects who received the former procedures not due to cerebral infarction more than 3 months ago, are eligible.
3. Subjects with hemorrhagic transformation on brain images, except for petechial hemorrhage ('H1' according to the ECASS classification)
4. Subjects at the high risk of developing brain herniation
5. History of dementia
6. History of epilepsy
7. Subjects who have been treated or diagnosed with schizophrenia, depression, or bipolar disorder within the past 6 months
8. Subjects with recent (≤3 months) myocardial infarction or stroke other than the index stroke.
9. Subjects must not have the following conditions in laboratory tests
* ALT or AST: More than 2.5 times the upper limit of normal
* Serum creatinine: More than 1.5 times the upper limit of normal
* Total bilirubin: More than 2.5 times the upper limit of normal
* Platelet count: less than lower limit of narmal
10. Subjects who are HBV, HCV, HIV, VDRL positive
11. Subjects in poor general condition due to medical conditions or subjects with severe cardiovascular, gastrointestinal, pulmonary, endocrinologic diseases
12. Subjects with active lung diseases, based on chest X-ray
13. Subjects with abnormal coagulopathic conditions (thrombocytopenia, congenital coagulopathy, etc.). Medical use of oral anticoagulants is permitted.
14. Subjects with known allergies to protein products (Bovine serum) used in the cell production process.
15. Subjects with history of pulmonary embolism or deep vein thrombosis
16. Subjects with history of malignancy
17. Pregnant or lactating women
18. Women of childbearing age who reject to practice contraception with one of the following methods
* Use a condom
* Use of contraceptive (oral, dermal, or injectable)
* Use an intra-uterine contraceptive device
19. Subjects with a history of alcohol abuse (\>30g/day) or drug abuse
20. Subjects who cannot undergo MRI scanning
21. Subjects who cannot conduct the scheduled monitoring visits
22. Subjects who is determined to be inappropriate by the investigators
19 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CHABiotech CO., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ok Joon Kim
Role: PRINCIPAL_INVESTIGATOR
CHA University Bundang Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHA-CST-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.